Double immunotherapy attack on aggressive lung cancer
Disease control
Terminated
This study is testing whether adding two immunotherapy drugs (monalizumab and durvalumab) to standard chemotherapy helps people with small cell lung cancer live longer without their cancer getting worse. It includes two groups: people with newly diagnosed advanced cancer and peop…
Phase: PHASE2 • Sponsor: Hirva Mamdani • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC